-
TAK-242 (Resatorvid) in TLR4 Assays
2026-08-10
This scenario-driven guide explains how TAK-242 (Resatorvid), a selective Toll-like receptor 4 (TLR4) inhibitor, can help researchers distinguish inflammatory signaling effects from genuine cytotoxicity in cell-based assays. It covers dose selection, DMSO handling, controls, interpretation, and vendor evaluation for SKU A3850.
-
LAG-3–TCR Proximity Controls T Cell Suppression
2026-08-09
A 2025 Cell study shows that LAG-3-mediated inhibition depends on spatial proximity to the T cell receptor, rather than MHC class II binding or CD4 association alone. The work identifies disruption of CD3ε–Lck signaling and develops an Fc-attenuated LAG-3/TCR bispecific antibody that suppresses pathogenic CD4+ and CD8+ T cells in autoimmune mouse models.
-
EV-Transferred ACLY Drives TAMs in HCC
2026-08-08
This study identifies extracellular vesicle-mediated transfer of ATP-citrate lyase (ACLY) as a metabolic mechanism that converts monocytes into immunosuppressive tumor-associated macrophages in hepatocellular carcinoma. Its liposome-based validation strategy suggests that selectively disrupting ACLY activity in TAMs may improve anti-PD-1/PD-L1 responses while limiting broader systemic effects.
-
Fluorinated-Sorbitol Polyplexes for mRNA Vaccines
2026-08-07
The reference study develops fluorinated polyethyleneimine functionalized with sorbitol (PFS) as a polymeric mRNA carrier that addresses two major delivery barriers: cellular uptake and endosomal escape. In cell and mouse experiments, PFS supported luciferase expression and enabled a SARS-CoV-2 spike mRNA vaccine to generate neutralizing responses comparable to a Moderna LNP formulation.
-
MCC950 Sodium: Precision NLRP3 Inflammasome Inhibition in Di
2026-08-07
MCC950 sodium (CRID3 sodium salt) empowers researchers to dissect NLRP3-driven inflammation with nanomolar specificity, unlocking new dimensions in inflammatory and autoimmune disease research. This guide details experimental workflows, protocol upgrades, and troubleshooting insights, leveraging APExBIO’s high-purity MCC950 sodium to achieve reproducible, high-impact results.
-
EV-Transferred ACLY Reprograms Monocytes in Liver Cancer Imm
2026-08-06
This study uncovers how hepatocellular carcinoma (HCC) cells use extracellular vesicles to deliver ATP-citrate lyase (ACLY) to monocytes, driving their differentiation into immunosuppressive tumor-associated macrophages (TAMs). The work reveals a novel mechanism of metabolic immune evasion in HCC and highlights ACLY as a potential target for improving immunotherapy.
-
Meropenem Trihydrate: Evidence-Based Insights for Carbapenem
2026-08-06
Meropenem trihydrate, a carbapenem antibiotic, offers robust activity against multidrug-resistant bacteria through inhibition of cell wall synthesis. It demonstrates low MIC90 values for key pathogens and is vital in resistance phenotype investigations. APExBIO's Meropenem trihydrate supports reproducible workflows in microbiological and infection biology research.
-
(-)-Arctigenin: MEK1 Inhibitor for NF-κB–Mediated Cancer Res
2026-08-05
(-)-Arctigenin is a high-purity bioactive small molecule MEK1 inhibitor with potent anti-inflammatory and antiviral properties. It modulates NF-κB signaling by suppressing IκBα phosphorylation and p65 nuclear translocation, with demonstrated IC50 values in the nanomolar range. This compound offers researchers a precise tool for dissecting tumor-immune signaling, but usage is strictly for scientific study and not for therapeutic application.
-
Targeted ROS-Responsive Nanoparticle Hydrogel for Diabetic P
2026-08-05
This study introduces a hierarchically targeted, ROS-responsive nanoparticle hydrogel that selectively repairs mitochondrial dysfunction in M1 macrophages to disrupt the inflammatory cascade of diabetic periodontitis. The platform achieves both targeted delivery and on-demand release, resulting in reduced periodontal inflammation and enhanced bone regeneration in preclinical models.
-
Exemestane: Steroidal Aromatase Inhibitor Workflows in Breas
2026-08-04
Exemestane stands out as a steroidal aromatase inhibitor with irreversible, substrate site-specific action, enabling robust estrogen biosynthesis inhibition in hormone-dependent cancer models. This article unpacks optimized protocols, advanced troubleshooting, and actionable insights for leveraging Exemestane from APExBIO in translational breast cancer research and beyond.
-
Enhancing Assay Reliability with (-)-Epinephrine (+)-bitartr
2026-08-04
This scenario-driven article addresses key laboratory challenges in cell viability and adrenergic signaling assays, demonstrating how (-)-Epinephrine (+)-bitartrate (SKU B1358) from APExBIO supports reproducible, sensitive research workflows. Evidence-backed guidance helps biomedical scientists optimize experimental design, interpret data, and select reliable reagents for cardiovascular, sympathetic nervous system, and neurobiology studies.
-
Amikacin Sulfate: Precision Intracellular Delivery for NTM R
2026-08-03
Amikacin Sulfate from APExBIO enables targeted, reproducible workflows for intracellular and granuloma-focused studies of non-tuberculous mycobacterial (NTM) and Staphylococcus aureus infections. This article delivers actionable protocol guidance, advanced troubleshooting, and comparative insights for maximizing experimental impact.
-
Tyrothricin’s Antimicrobial Peptide Mechanisms: From Membran
2026-08-03
Explore Tyrothricin, a peptide antibiotic mixture, through a deep analysis of its membrane-targeting antimicrobial mechanisms and their implications for advanced infection research. This article uniquely connects mechanistic insights with contemporary assay strategy, setting it apart from existing protocol-driven overviews.
-
EV-Transferred ACLY Drives TAM Differentiation in Liver Canc
2026-08-02
This study reveals that hepatocellular carcinoma (HCC)-derived extracellular vesicles transfer ATP-citrate lyase (ACLY) to monocytes, triggering their differentiation into immunosuppressive tumor-associated macrophages (TAMs). Targeting this EV-mediated metabolic axis offers a promising strategy to improve immunotherapeutic outcomes in HCC.
-
Sulfo-NHS-SS-Biotin: Protocols for Cleavable Protein Labelin
2026-08-01
Sulfo-NHS-SS-Biotin addresses the need for efficient, reversible biotinylation of proteins containing primary amines—particularly for labeling cell surface proteins in aqueous systems. It is unsuitable for intracellular labeling or for protocols requiring extended reagent stability in solution.